BRIDGING EVIDENCE AND ACCESS: SURVEY-BASED INSIGHTS INTO HOW BIOPHARMACEUTICAL MANUFACTURERS DEVELOP AND SHARE HCEI RESOURCES
Author(s)
Tahira Farmer, MPH, Jack Badaracco, MS, PharmD, Brian Duffant, BS, Matthew Gitlin, PharmD;
BluePath Solutions, Los Angeles, CA, USA
BluePath Solutions, Los Angeles, CA, USA
OBJECTIVES: Health care economic information (HCEI) supports manufacturer and payer discussions about a product’s clinical and economic value for coverage decisions. While prior surveys focused on payer perceptions, we surveyed manufacturers to understand how they are keeping track with payer needs in order to identify common practices, challenges, and emerging innovations.
METHODS: A web-based survey was administered to a convenience sample of direct and indirect stakeholders involved in the development of HCEI resources. Decision makers included stakeholders such as but not limited to functions responsible for strategy and tactics, evidence generation, communication and dissemination. The survey consisted of 40 questions covering topics including organizational profile, HCEI evidence categories, resource conceptualization, development and approval processes, dissemination tactics, innovation, and post-dissemination assessment.
RESULTS: A total of 26 respondents were surveyed, with the majority coming from evidence generation function (50%), serving a senior role (65%) within a large (>10 commercialized products) organization (74%). Most produced over 6 HCEI resources annually; development and approval often take between 6-12 months, with 12-31% reporting timelines over 12 months. Cross-functional collaboration is central, with Evidence and Payer Marketer teams involved 96% and 85% of the time respectively. Roughly 58-65% of manufacturers tailor affordability and value evidence to specific payer customer types. Dossiers and interactive models are primary tactics for sharing affordability and value evidence, while real world evidence is usually delivered through dossiers and simplified summaries such as slide decks rather than interactive or static models.
CONCLUSIONS: HCEI work is complex and requires foresight, as approval teams often differ from development teams. The prevalence of customer specific materials suggests that focused, purpose built resources outperform one-size-fits-all approaches. Strong situational analysis, customer engagement, and targeted evidence generation remain essential to ensure each resource is truly fit for purpose.
METHODS: A web-based survey was administered to a convenience sample of direct and indirect stakeholders involved in the development of HCEI resources. Decision makers included stakeholders such as but not limited to functions responsible for strategy and tactics, evidence generation, communication and dissemination. The survey consisted of 40 questions covering topics including organizational profile, HCEI evidence categories, resource conceptualization, development and approval processes, dissemination tactics, innovation, and post-dissemination assessment.
RESULTS: A total of 26 respondents were surveyed, with the majority coming from evidence generation function (50%), serving a senior role (65%) within a large (>10 commercialized products) organization (74%). Most produced over 6 HCEI resources annually; development and approval often take between 6-12 months, with 12-31% reporting timelines over 12 months. Cross-functional collaboration is central, with Evidence and Payer Marketer teams involved 96% and 85% of the time respectively. Roughly 58-65% of manufacturers tailor affordability and value evidence to specific payer customer types. Dossiers and interactive models are primary tactics for sharing affordability and value evidence, while real world evidence is usually delivered through dossiers and simplified summaries such as slide decks rather than interactive or static models.
CONCLUSIONS: HCEI work is complex and requires foresight, as approval teams often differ from development teams. The prevalence of customer specific materials suggests that focused, purpose built resources outperform one-size-fits-all approaches. Strong situational analysis, customer engagement, and targeted evidence generation remain essential to ensure each resource is truly fit for purpose.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
OP9
Topic
Organizational Practices
Topic Subcategory
Industry
Disease
No Additional Disease & Conditions/Specialized Treatment Areas